Predictors of ovarian sensitivity to gonadotropins: a multicentric retrospective investigation of 1,942 women candidates to ART
This multicentric retrospective study of 1,942 women undergoing ART cycles identifies chronological age and anti-Müllerian hormone (AMH) as the primary negative and positive predictors, respectively, of ovarian sensitivity to gonadotropins as measured by the Follicle output rate and Follicle to Oocytes Index.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the world of assisted reproduction, the goal is often to gather as many healthy eggs as possible from a woman's ovaries to create embryos. For decades, doctors have relied on two main tools to guess how a woman will respond to the hormones used to stimulate egg growth. One tool is a simple count of the small, resting eggs visible on an ultrasound, known as the antral follicle count. The other is a blood test measuring a hormone called anti-Müllerian hormone, or AMH, which acts as a chemical signal of the remaining egg supply. While these markers are excellent for estimating the total number of eggs a woman might have, they do not always tell the full story of how well the ovaries will actually work when stimulated. It is not uncommon for a woman with a good number of resting eggs to produce far fewer mature eggs than expected after treatment. This gap between what is expected and what is achieved is a critical puzzle for fertility specialists, who need to understand why some ovaries seem less sensitive to the medication than others.
To solve this puzzle, a large team of researchers from India and Italy conducted a massive review of medical records to see what factors truly predict how well an ovary responds to stimulation. They looked at data from nearly 82,000 treatment cycles, eventually narrowing their focus to 1,942 women who met very specific criteria. These women were between the ages of 21 and 40, had a body mass index between 18.5 and 30, and received a standard daily dose of fertility hormones. The researchers excluded women who used donor eggs or different types of medication triggers to ensure the results were not skewed by unusual variables. Instead of just counting the final eggs, the team used two new ways to measure efficiency. The first method, called the Follicle-to-Oocyte Index, compares the number of eggs collected to the number of resting follicles seen at the start. The second method, the Follicle Output Rate, looks at the ratio of follicles that actually grew large enough to be retrieved versus those that remained small. These metrics essentially measure how efficiently the treatment turned the available potential into actual results.
The analysis revealed a clear and consistent pattern. The researchers found that as a woman's age increased, her ovaries became less efficient at converting resting follicles into mature eggs. This decline was observed across the board, regardless of how many resting follicles a woman started with. Conversely, women with higher levels of the AMH hormone showed a better ability to produce eggs relative to their starting count. The study also looked at body weight and found a very slight, though statistically noticeable, trend where higher body mass index was associated with a slightly lower efficiency in egg production. However, the most powerful predictors remained age and the AMH level. When the researchers built a mathematical model to see which factors mattered most, they found that age and AMH were the only two variables that consistently explained the differences in ovarian sensitivity.
One of the most interesting nuances in the findings was how age affected the two different measurements. While older age was linked to lower efficiency in both metrics, the effect was more pronounced on the Follicle-to-Oocyte Index than on the Follicle Output Rate. This suggests that as women age, the issue may not just be about the number of eggs that grow, but also about the quality or the specific biological steps required to turn a growing follicle into a retrievable egg. The study suggests that while the total number of eggs is important, the biological age of the ovaries, reflected by the AMH level, is a more precise indicator of how well the system will function under stimulation. The researchers noted that their findings come from a single center with a highly uniform treatment protocol, which reduces the chance of errors caused by different methods but also means the results need to be confirmed in other populations with different ethnic backgrounds and medical practices.
Ultimately, this work offers a clearer way to look at ovarian health. It moves beyond simply counting eggs to understanding the dynamic relationship between what a woman starts with and what she achieves. The study suggests that age and AMH are the most important guides for predicting how sensitive the ovaries will be to fertility drugs. By focusing on these two factors, doctors may be better equipped to understand why some women respond differently than expected, even when they appear to have a similar starting point. The researchers conclude that these new ways of measuring efficiency are valuable tools, but they emphasize that larger studies involving diverse groups of people are needed to fully confirm these patterns and refine how they are used in clinical practice.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.